# Ovid Therapeutics Inc.: financial statements, quarterly

OVID · Nasdaq · CIK 1636651 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ovid.md) · [Financials](/companies/ovid/financials.md) · [Filings](/companies/ovid/filings.md) · [Insiders](/companies/ovid/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ovid/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001628280-24-046868.md) | [0.1 d](/filings/0001628280-25-011844.md) | [0.1](/filings/0001628280-25-024913.md) | [0.2](/filings/0001628280-25-040008.md) | [0.2](/filings/0001636651-25-000012.md) | [0.1 d](/filings/0001628280-26-019438.md) | [0.1](/filings/0001628280-26-033864.md) | [6.3](/filings/0001628280-26-056498.md) | [0.1](/filings/0001636651-25-000012.md) | [0.7 d](/filings/0001628280-26-019438.md) | [0.0](/filings/0001628280-26-033864.md) | [0.7](/filings/0001628280-26-056498.md) |
| Research and development | $m | [5.3](/filings/0001628280-24-046868.md) | [10.6 d](/filings/0001628280-25-011844.md) | [10.4](/filings/0001628280-25-024913.md) | [12.6](/filings/0001628280-25-040008.md) | [7.9](/filings/0001636651-25-000012.md) | [5.9 d](/filings/0001628280-26-019438.md) | [6.7](/filings/0001628280-26-033864.md) | [6.5](/filings/0001628280-26-056498.md) | [5.9](/filings/0001636651-25-000012.md) | [6.6 d](/filings/0001628280-26-019438.md) | [11.2](/filings/0001628280-26-033864.md) | [10.0](/filings/0001628280-26-056498.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(12.0)](/filings/0001628280-24-046868.md) | [(18.2) d](/filings/0001628280-25-011844.md) | [(17.4)](/filings/0001628280-25-024913.md) | [(20.5)](/filings/0001628280-25-040008.md) | [(13.2)](/filings/0001636651-25-000012.md) | [(10.7) d](/filings/0001628280-26-019438.md) | [(12.6)](/filings/0001628280-26-033864.md) | [(5.1)](/filings/0001628280-26-056498.md) | [(12.5)](/filings/0001636651-25-000012.md) | [(12.3) d](/filings/0001628280-26-019438.md) | [(17.8)](/filings/0001628280-26-033864.md) | [(15.7)](/filings/0001628280-26-056498.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-046868.md) | [0.0 d](/filings/0001628280-25-011844.md) | [0.0](/filings/0001628280-25-024913.md) | [0.0](/filings/0001628280-25-040008.md) | [0.0](/filings/0001636651-25-000012.md) | [0.0 d](/filings/0001628280-26-019438.md) | [0.0](/filings/0001628280-26-033864.md) | [0.0](/filings/0001628280-26-056498.md) | [0.0](/filings/0001636651-25-000012.md) | [0.0 d](/filings/0001628280-26-019438.md) | [0.0](/filings/0001628280-26-033864.md) | [0.0](/filings/0001628280-26-056498.md) |
| Net income | $m | [(11.3)](/filings/0001628280-24-046868.md) | [(15.3) d](/filings/0001628280-25-011844.md) | [(11.7)](/filings/0001636651-25-000012.md) | [8.5](/filings/0001636651-25-000012.md) | [(14.0)](/filings/0001636651-25-000012.md) | [(9.3) d](/filings/0001628280-26-019438.md) | [(10.2)](/filings/0001628280-26-056498.md) | [(4.7)](/filings/0001628280-26-056498.md) | [(12.2)](/filings/0001636651-25-000012.md) | [9.7 d](/filings/0001628280-26-019438.md) | [(17.0)](/filings/0001628280-26-056498.md) | [(15.0)](/filings/0001628280-26-056498.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001628280-24-046868.md) | not reported | [(0.17)](/filings/0001628280-24-023067.md) | [0.12](/filings/0001628280-24-036860.md) | [(0.20)](/filings/0001628280-24-046868.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.16)](/filings/0001628280-24-046868.md) | not reported | [(0.17)](/filings/0001628280-24-023067.md) | [0.12](/filings/0001628280-24-036860.md) | [(0.20)](/filings/0001628280-24-046868.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [57.4](/filings/0001628280-23-036564.md) | [27.0](/filings/0001628280-25-011844.md) | [30.8](/filings/0001628280-24-023067.md) | [29.7](/filings/0001628280-24-036860.md) | [15.0](/filings/0001628280-24-046868.md) | [26.3](/filings/0001628280-26-019438.md) | [21.1](/filings/0001628280-25-024913.md) | [28.4](/filings/0001628280-25-040008.md) | [20.6](/filings/0001636651-25-000012.md) | [13.2](/filings/0001628280-26-056498.md) | [94.1](/filings/0001628280-26-033864.md) | [11.3](/filings/0001628280-26-056498.md) |
| Current assets | $m | [91.7](/filings/0001628280-23-036564.md) | [110](/filings/0001628280-25-011844.md) | [93.2](/filings/0001628280-24-023067.md) | [80.9](/filings/0001628280-24-036860.md) | [65.8](/filings/0001628280-24-046868.md) | [55.9](/filings/0001628280-26-019438.md) | [45.9](/filings/0001628280-25-024913.md) | [42.1](/filings/0001628280-25-040008.md) | [28.8](/filings/0001636651-25-000012.md) | [74.4](/filings/0001628280-26-056498.md) | [160](/filings/0001628280-26-033864.md) | [124](/filings/0001628280-26-056498.md) |
| Total assets | $m | [125](/filings/0001628280-23-036564.md) | [144](/filings/0001628280-25-011844.md) | [132](/filings/0001628280-24-023067.md) | [118](/filings/0001628280-24-036860.md) | [103](/filings/0001628280-24-046868.md) | [92.2](/filings/0001628280-26-019438.md) | [81.7](/filings/0001628280-25-024913.md) | [77.4](/filings/0001628280-25-040008.md) | [63.8](/filings/0001636651-25-000012.md) | [151](/filings/0001628280-26-056498.md) | [226](/filings/0001628280-26-033864.md) | [232](/filings/0001628280-26-056498.md) |
| Current liabilities | $m | [8.7](/filings/0001628280-23-036564.md) | [11.5](/filings/0001628280-25-011844.md) | [8.9](/filings/0001628280-24-023067.md) | [14.1](/filings/0001628280-24-036860.md) | [11.6](/filings/0001628280-24-046868.md) | [10.5](/filings/0001628280-26-019438.md) | [9.3](/filings/0001628280-25-024913.md) | [8.9](/filings/0001628280-25-040008.md) | [6.8](/filings/0001636651-25-000012.md) | [8.3](/filings/0001628280-26-056498.md) | [15.7](/filings/0001628280-26-033864.md) | [10.0](/filings/0001628280-26-056498.md) |
| Total liabilities | $m | [23.7](/filings/0001628280-23-036564.md) | [56.2](/filings/0001628280-25-011844.md) | [53.3](/filings/0001628280-24-023067.md) | [29.2](/filings/0001628280-24-036860.md) | [26.4](/filings/0001628280-24-046868.md) | [23.9](/filings/0001628280-26-019438.md) | [22.4](/filings/0001628280-25-024913.md) | [21.6](/filings/0001628280-25-040008.md) | [19.2](/filings/0001636651-25-000012.md) | [20.3](/filings/0001628280-26-056498.md) | [27.4](/filings/0001628280-26-033864.md) | [22.1](/filings/0001628280-26-056498.md) |
| Shareholders' equity | $m | [101](/filings/0001628280-24-046868.md) | [87.8](/filings/0001628280-26-019438.md) | [78.3](/filings/0001636651-25-000012.md) | [88.9](/filings/0001636651-25-000012.md) | [76.3](/filings/0001636651-25-000012.md) | [68.2](/filings/0001628280-26-056498.md) | [59.3](/filings/0001628280-26-056498.md) | [55.8](/filings/0001628280-26-056498.md) | [44.7](/filings/0001636651-25-000012.md) | [131](/filings/0001628280-26-056498.md) | [198](/filings/0001628280-26-056498.md) | [210](/filings/0001628280-26-056498.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.1) d](/filings/0001628280-24-046868.md) | [(11.9) d](/filings/0001628280-25-011844.md) | [(16.7)](/filings/0001628280-25-024913.md) | [(14.3) d](/filings/0001628280-25-040008.md) | [(15.0) d](/filings/0001636651-25-000012.md) | [(10.0) d](/filings/0001628280-26-019438.md) | [(10.3)](/filings/0001628280-26-033864.md) | [(4.8) d](/filings/0001628280-26-056498.md) | [(12.9) d](/filings/0001636651-25-000012.md) | [(10.4) d](/filings/0001628280-26-019438.md) | [(13.9)](/filings/0001628280-26-033864.md) | [(17.6) d](/filings/0001628280-26-056498.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-046868.md) | [0.0 d](/filings/0001628280-25-011844.md) | [0.0](/filings/0001628280-25-024913.md) | [0.0 d](/filings/0001628280-25-040008.md) | [(0.0) d](/filings/0001636651-25-000012.md) | [0.0 d](/filings/0001628280-26-019438.md) | [0.0](/filings/0001628280-25-024913.md) | [0.0 d](/filings/0001628280-25-040008.md) | [0.0 d](/filings/0001636651-25-000012.md) | [0.0 d](/filings/0001628280-26-019438.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [66.6](/filings/0000950170-22-008739.md) | [67.8](/filings/0001628280-22-021759.md) | [67.9](/filings/0001628280-22-028772.md) | [70.3](/filings/0001628280-23-016013.md) | [70.4](/filings/0001628280-23-027430.md) | [70.4](/filings/0001628280-23-036564.md) | [70.5](/filings/0001628280-24-023067.md) | [70.5](/filings/0001628280-24-036860.md) | [70.6](/filings/0001628280-24-046868.md) | [70.7](/filings/0001628280-24-023067.md) | [71.2](/filings/0001628280-24-036860.md) | [71.0](/filings/0001628280-24-046868.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 195,297,857 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001628280-26-056498.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.